+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the safety and effects of a new medicine called etavopivat in treating pediatric patients with sickle cell disease who are at increased risk for primary stroke. Participants will be grouped based on their transcranial doppler TCD ultrasound results and whether they are taking hydroxyurea, a medication already used for this condition. The study focuses on those with conditional or abnormal TCD results, with the study doctor determining the classification. This is a phase 2, open-label trial designed to assess etavopivats activity on blood flow velocities in key brain arteries. Participants will receive 400 mg of etavopivat orally once daily for a 52-week treatment period. This dose consists of two 200 mg tablets taken with water, with or without food. Participants are divided into two cohorts one receiving etavopivat alone, and another receiving etavopivat in combination with a stable dose of hydroxyurea. After the initial treatment period, there is an optional 48-week extension to further evaluate the safety of etavopivat in pediatric patients. At the studys conclusion, participants may have the option to join a separate study to continue etavopivat treatment. Throughout the study, participants will visit the clinic frequently for assessments, including transcranial doppler ultrasound measurements to track blood flow velocities at various time points. Researchers will monitor changes in the highest time-averaged maximum mean velocities TAMMV in the internal carotid and middle cerebral arteries, as well as the incidence of changes in TCD velocity categories. Safety and treatment effects will be closely observed during both the primary and optional extension periods, with total participation lasting up to 100 weeks if the extension is chosen.

Age: 12Years - 16YearsAll GendersPhase 2
9 locations
S

Actively Recruiting

Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.

Age: 12Years +All GendersPhase 2Phase 3
80 locations
L

Actively Recruiting

Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.

Age: 2Years +All GendersPhase 3
107 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
P

Actively Recruiting

Researchers are evaluating the safety, immune response, and consistency between different vaccine lots of BBV87, an inactivated Chikungunya virus vaccine, in healthy individuals aged 12 to 65 years. This Phase IIIII clinical trial is randomized, observer-blind, and placebo-controlled, aiming to understand how well the vaccine works and its safety profile across multiple study centers. Participants will be randomly assigned to receive one of three lots of the BBV87 vaccine or a placebo. Each subject will receive two doses of 40 micrograms administered as injections into the deltoid muscle of the arm, with the second dose given about 28 days after the first. Safety data will be reviewed by an independent board during the study to ensure participant protection. During the study, participants will attend visits for vaccination and follow-up assessments, including blood tests to measure antibody levels against the virus 28 days after each dose. Researchers will monitor for any adverse events for up to 11 months post-vaccination. The main outcomes measured include immune response levels and the percentage of participants who develop antibodies, along with the safety and tolerability of the vaccine.

Age: 12Years - 65YearsAll GendersPhase 2Phase 3
10 locations
M

Actively Recruiting

Researchers are evaluating the efficacy and safety of eloralintide in adults with moderate-to-severe obstructive sleep apnea OSA who are also obese or overweight. The study uses a master protocol called YDAO that includes two separate studies YSA1 for participants who cannot or do not want to use Positive Airway Pressure PAP therapy, and YSA2 for those who have been on PAP therapy for at least three months and plan to continue it during the study. The goal is to understand how eloralintide affects body weight and sleep apnea severity. Participants will be randomly assigned to receive either eloralintide or a placebo, both given as weekly subcutaneous injections. The study lasts about 76 weeks and includes two groups based on PAP therapy use. During the study, participants will continue their current PAP therapy status according to their assigned group. The study is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the study, participants will undergo assessments at baseline and Week 64, including measuring changes in body weight, apnea-hypopnea index AHI, blood pressure, triglycerides, sleep-related impairment, and other health markers. Researchers will also monitor safety, medication use, and pharmacokinetics. Participants can expect regular visits for evaluations and monitoring over the study period to understand the effects of eloralintide on OSA and obesity-related health factors.

Age: 18Years +All GendersPhase 3
115 locations
O

Actively Recruiting

Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.

Age: 50Years +All GendersPhase 3
566 locations
P

Actively Recruiting

Researchers are evaluating the use of SNP-ACTH 1-39 Gel compared to rituximab for treating adults with primary membranous nephropathy PMN, a kidney condition. This trial uses a two-phase adaptive design to find the best dose of SNP-ACTH Gel and then assess its effectiveness against rituximab. The study is divided into Phase 3a for dose finding and Phase 3b for comparing treatments over 24 months. In Phase 3a, up to 24 patients will be randomly assigned to receive either 3 mg or 5 mg of SNP-ACTH Gel by subcutaneous injection three times a week for 12 months. Data from this phase will guide dose selection for Phase 3b. In Phase 3b, 132 patients will be randomized to receive either the selected dose of SNP-ACTH Gel for 12 months or rituximab infusions given in two cycles, one at the start and one at six months. Participants will be monitored throughout the study with regular assessments of urinary protein and auto-antibody levels during Phase 3a, and clinical responses at 24 months in Phase 3b. Researchers will track kidney function, relapse rates, immune responses, and safety outcomes. Study visits and evaluations will occur at multiple time points up to two years, supporting detailed understanding of treatment effects and patient health over time.

Age: 18Years +All GendersPhase 3
31 locations
E

Actively Recruiting

Researchers are evaluating centhaquine citrate LYFAQUIN1, a novel drug being studied as a resuscitative agent for adults with hypovolemic shock, which is a life-threatening condition caused by severe blood or fluid loss. This phase IV, open-label, multi-center study aims to assess the safety and efficacy of centhaquine when added to the standard shock treatment. Centhaquine acts on specific receptors to improve blood flow and reduce vascular resistance, with prior studies showing promising effects on blood pressure, lactate levels, cardiac output, and mortality in animal models. Participants aged 18 years or older with hypovolemic shock and low systolic blood pressure 90 mmHg or lower will receive centhaquine intravenously at a dose of 0.01 mgkg body weight over one hour, in addition to standard care such as fluid resuscitation and vasopressors. A second dose may be given if blood pressure remains low, with no more than three doses in 24 hours and treatment continuing up to two days after enrollment. Each patient will receive between one and six doses within the first 48 hours. Throughout hospitalization, participants will be monitored closely until discharge or up to seven days after joining the trial. Researchers will assess safety by tracking adverse events and efficacy by measuring blood pressure, lactate levels, base deficit, ICU stay duration, ventilator use, urine output, mortality, organ dysfunction scores, respiratory distress, and neurological status. Statistical analyses will compare patient outcomes to understand centhaquines effects as an addition to standard hypovolemic shock treatment.

Age: 18Years +All GendersPhase 4
17 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide at different dose levels compared to a placebo in adults with uncontrolled moderate to severe asthma. The study aims to understand how brenipatide impacts asthma control and exacerbation rates over time. This phase 2, randomized, double-blind trial involves participants aged 18 to 75 years who have a history of asthma and recent asthma exacerbations. Participants will receive either one of two doses of brenipatide or a placebo, all administered by subcutaneous injection. The treatment period lasts 52 weeks, during which the effects of the study drug on asthma symptoms and lung function will be monitored. The study includes screening, treatment, and follow-up phases, with the overall participation lasting about 65 weeks. During the trial, participants will undergo assessments such as lung function tests, health questionnaires, and monitoring for asthma exacerbations and medication use. Blood samples may be collected to study the drugs behavior in the body and the immune response. Researchers will track safety and treatment effects throughout the study and during follow-up to understand the long-term impact of brenipatide on asthma control.

Age: 18Years - 75YearsAll GendersPhase 2
119 locations

1-10 of 17

1